Analyst Rating: Will F-Star Therapeutics Inc (FSTX) Stock Outperform the Market?

Thursday, February 16, 2023 01:03 PM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will F-Star Therapeutics Inc (FSTX) Stock Outperform the Market?

Wall Street is positive on F-Star Therapeutics Inc (FSTX). On average, analysts give the stock a Hold rating. The average price target is $7, which means analysts expect the stock to rise by 42.57% over the next twelve months. That average ranking earns the stock an Analyst Rating of 6, which is better than 6% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating FSTX a Hold today. Find out what this means to you and get the rest of the rankings on FSTX!

See Full FSTX Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With F-Star Therapeutics Inc Stock Today?

F-Star Therapeutics Inc (FSTX) stock has risen 2.31% while the S&P 500 has fallen -0.37% as of 1:03 PM on Thursday, Feb 16. FSTX has risen $0.11 from the previous closing price of $4.80 on volume of 86,614 shares. Over the past year the S&P 500 has fallen -7.66% while FSTX has risen 28.20%. FSTX lost -$2.07 per share the over the last 12 months. Click Here to get the full Stock Report for F-Star Therapeutics Inc stock.